Targeting therapeutic resistance in glioblastoma (GBM)
Official title: Targeting therapeutic resistance in glioblastoma
Funded at VA Boston Health Care System · NIH-11305233 · Data updated 2026-11-12
A patient-facing description of a project to help people with glioblastoma by tackling drug resistance in brain tumor cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Boston Health Care System NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2031 |
| Funding year | 2027 |
| NIH project number | 5I01BX006004-04 |
| Project ID | NIH-11305233 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with glioblastoma, particularly those whose tumors express ABCB5 or related resistance markers, could be eligible in future studies.
✕Less likely to help
If the tumor does not rely on ABCB5 for resistance, or if participants have different molecular profiles, benefits may be limited.
What this research studies
This project focuses on glioblastoma, a very aggressive brain cancer, and aims to find ways to overcome why tumorsstop responding to current treatments. Researchers are studying cancer stem cell subtypes and a protein called ABCB5 that appears to help GBM cells resist therapy. The work builds on prior findings that link ABCB5 to poorer outcomes and drug resistance in GBM. By understanding how ABCB5 contributes to resistance, scientists hope to develop strategies that make treatments more durable for patients. The study is conducted here at VA Boston Health Care System with the aim of improving future options for people living with GBM.
Why it matters
Potential benefit: If successful, the work could lead to therapies that overcome resistance and extend survival for GBM patients.
How similar studies have gone: Previous studies have linked ABCB5 to drug resistance and stem-like properties in GBM, with some preclinical success in overcoming resistance.
Where this research is happening
-
VA Boston Health Care System
Boston, United States Active
Researchers
- Principal investigator: Frank, Natasha Y — VA Boston Health Care System
- Study coordinator: Frank, Natasha Y
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.